G-Protein-Coupled Receptor CXCR7 Is Overexpressed in Human and Murine Endometriosis

Reproductive Sciences
2018, Vol. 25(8) 1168-1174
© The Author(s) 2018
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/1933719118766256
journals.sagepub.com/home/rsx

Nicola Pluchino, MD, PhD¹, Ramanaiah Mamillapalli, PhD¹ ,
Irene Moridi, MD¹, Reshef Tal, MD, PhD¹, and Hugh S. Taylor, MD¹

Abstract

Endometriosis is a chronic inflammatory disease. Dysfunctional regulation of chemokines and chemokine receptors is a crucial aspect of endometriosis pathogenesis. Chemokine G-protein-coupled receptors (GPCRs) are important drug targets that regulate inflammation and immunity. Recently, *CXCR7*, a C-X-C motif containing GPCR, has been identified as a receptor for chemokine ligand *CXCL12*, one of the best characterized chemokines for cell trafficking, angiogenesis, and cell proliferation in cancer and inflammation. Here, we investigated the expression and localization of *CXCR7* in human endometriosis and a murine model of the disease. Normal endometrial epithelium and stroma showed undetectable or very low expression of *CXCR7*, without any significant changes across phases of the menstrual cycle in humans. *CXCR7* is significantly upregulated in endometriosis, showing higher staining in glands and in associated vessels. The mouse model recapitulated the human findings. In conclusion, overexpression of *CXCR7* in different cellular populations of endometriosis microenvironment may play a role in the pathogenesis and represent a novel target for treatment.

Keywords

endometriosis, *CXCR7*, *CXCL12*, human, murine, microenvironment

Introduction

Endometriosis is a common gynecologic disorder characterized by the presence of hormonally responsive ectopic implants of endometrial epithelium and stroma dispersed in extra-uterine locations.¹⁻⁴ Although the etiology is not fully characterized, endometriosis is a multifactorial disorder, resulting from retrograde menstruation,⁵ ectopic differentiation of stem cells,⁶⁻⁸ dysregulation of immune/inflammatory cells,⁹ and abnormal hormonal response.¹⁰⁻¹² Chemokines are a group of small chemotactic cytokine proteins (<15 kDa) secreted by various cell types after induction or which may be constitutively expressed. They are divided into 4 groups: CXC, CC, C, and CX3C based on the number and position of conserved cysteine residues (cysteine motif) in the N-terminal region of the protein.¹³⁻¹⁵ They exert functional effects by binding to their corresponding receptors.¹⁶ *CXCL12*, also known as stromal cell-derived factor 1 (SDF-1), is a chemokine ligand and one of the best characterized chemokines in mobilization of BM-derived stem cells in cancer and inflammation.¹⁷ In the endometriosis niche, *CXCL12* participates in epithelial/glandular cell proliferation via autocrine/paracrine mechanisms,^{18,19} vasculogenesis, and angiogenesis.²⁰

CXCR4 is a G-protein-coupled receptor (GPCR) for *CXCL12* and expressed on bone marrow-derived mesenchymal

stem cells, solid tumors, and endometriosis implants. *CXCL12-CXCR4* signaling is upregulated in women with endometriosis²¹⁻²⁴ and has been established as a crucial signal for bone marrow-derived cells (BMDCs) migration to endometriosis.²⁵ Recently, *CXCR7*, another GPCR, has been identified as a second receptor for *CXCL12*.^{26,27} *CXCR7*, which is phylogenetically closely related to other chemokine receptors, binds SDF-1 with high affinity and the alternative ligand *CXCL11* with low affinity;²⁸ however, it fails to couple to G-proteins to induce typical chemokine receptor-mediated cellular responses.²⁹ *CXCR7* has been demonstrated to regulate cell migration and survival through several pathways that include ligand scavenging, direct signal transduction, and direct interaction with *CXCR4*.^{28,30,31} *CXCR7* expression is enhanced during pathological inflammation and tumor development, and *CXCR7* mediates transforming growth factor β 1 (TGF β 1)-

¹ Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA

Corresponding Author:

Ramanaiah Mamillapalli, Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA.

Email: ramana.mamillapalli@yale.edu

promoted epithelial–mesenchymal transition.³² Emerging data suggest that this receptor is an attractive therapeutic target for autoimmune diseases and cancer.³³ Although human endometriosis implants have higher *CXCL12* and *CXCR4* expression,^{21,25} no information is currently available on *CXCR7*. Here, we report the expression of *CXCR7* in human endometriosis and in a murine model of abdominal endometriosis.

Materials and Methods

Human Sample Collection and Analysis

Tissue samples consisting of peritoneal lesions were collected from 11 patients (after excluding criteria) with severe endometriosis [American Fertility Society (AFS) stage IV] at the time of surgery and following a Human Investigation Committee protocol approved by Yale University. Fresh endometrial tissue was collected as controls from 11 healthy, reproductive age women undergoing elective gynecological surgery, without evidence of uterine diseases or endometriosis. Among 11 normal healthy women, 6 were in proliferative phase while 5 were in secretory phase. Women who received exogenous hormonal therapy in the 3 months before tissue collection or had endometrial pathology were excluded. Collected tissue samples were processed immediately; an aliquot of tissue stored at -80°C in RNeasy lysis buffer for RNA isolation and the remaining tissue was stored in 4% formaldehyde overnight and processed for histological studies.

Animals

C57BL/6J wild-type mice were purchased from Charles River Laboratories (Wilmington, Massachusetts) and The Jackson Laboratory (Bar Harbor, Maine), respectively. Mice were housed and maintained (4–5 per cage) in a room ($21^{\circ}\text{C} \pm 1^{\circ}\text{C}$) with a 12-hour light/dark cycle (7:00 AM to 7:00 PM) with ad libitum access to food (Purina Chow; Purina Mills, Richmond, Indiana) and water, in the Yale Animal Resources Center (YARC) at Yale School of Medicine. All animal experiments were conducted in accordance with an approval protocol from the Yale University Institutional Animal Care and Use Committee (IACUC).

Mouse Model of Endometriosis

Endometriosis in mice was surgically induced under aseptic conditions and anesthesia using a modified method previously described.³⁴ Uterine horns were removed from wild-type female donor mice at diestrus, opened longitudinally, cut into fragments of 3 mm, and transplanted onto the peritoneal wall of recipient mice and affixed with absorbable suture. Three lesions of equal size were systematically transplanted in each mouse. Ectopic tissues were collected 2 weeks and 4 weeks after grafting.

Quantitative Real-Time Polymerase Chain Reaction

Total RNA was isolated from endometriotic lesions by TRIzol reagent (Life Technologies, Carlsbad, California) followed by purification using Qiagen cleaning kit (Valencia, California) to prepare cDNA with 50 ng RNA in a 20- μL reaction mixture by iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, California). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to quantify gene expression using specific primers and SYBR Green (Bio-Rad Laboratories) and optimized in the MyiQ Single Color Real-Time PCR Detection System (Bio-Rad Laboratories). The primers used are *CXCL12*: forward 5'-AACACTCCAACTGTGCCCT-3', reverse 5'-CTCTCACATCTTGAACCTCTTGTT-3'; *CXCR7*: forward 5'-GCAGAGCTCACAGTTGTTGC-3', reverse 5'-GCTGATGTCCGAGAAGTTCC-3'.

The specificity of the amplified transcript and the absence of primer dimers were confirmed by a melting curve analysis. Gene expression was normalized to the expression of β -actin for each sample. Relative mRNA expression for each gene was calculated using the comparative cycle threshold (Ct) method, also known as the $2^{-\Delta\Delta\text{Ct}}$ method.^{35,36} All experiments were carried out in triplicate, and nuclease-free water was used as a negative control replacing the cDNA template.

Immunohistochemistry

Tissue samples from patients with endometriosis and endometriotic lesions from mice were fixed in 4% paraformaldehyde and embedded in paraffin. Five-micrometer tissue sections were mounted on slides followed by 10 minutes boiling in sodium citrate (pH 6) for antigen retrieval and blocking using 10% serum (Vector Laboratories, Burlingame, California). Slides were incubated at 4°C overnight with anti-CXCR7 primary antibody clone 11G8 (1:1000; R & D Systems, Minneapolis, Minnesota) followed by 30 minutes at room temperature with appropriate biotinylated secondary antibody (1:200; Vector Laboratories, Burlingame, California), and detected using ABC Vectastain Elite reagents with DAB plus H_2O_2 (Vector Laboratories, Burlingame, California). Tissue sections were counterstained with hematoxylin (Sigma-Aldrich, St. Louis, Missouri). Images of stained sections were captured using Olympus BX-51 microscope (Olympus, Waltham, MA, USA). Stained cells were quantified by monitoring the average numbers of positively stained cells relative to the total number of cells from 6 randomly chosen fields.

Statistical Analysis

Data were analyzed using Prism (GraphPad Software Inc, La Jolla, California). An unpaired Student *t* test or one-way analysis of variance (ANOVA) was used to determine the statistical significance between mRNA expression levels. Data are expressed as means $\pm$ SEM. The Mann-Whitney rank followed by Dunn's test was used to compare percentage of labeled cells (PLC). *P* value $< .05$ was considered significant.

Figure 1. CXCR7 expression. A, Expression of CXCR7 mRNA levels in eutopic normal endometrium (proliferative phase set as baseline and equal to 1.0) and ectopic endometriosis. CXCR7 mRNA levels were significantly increased in ectopic endometriosis. B, Quantitative analyses of the levels of CXCR7 in human normal endometrium during proliferative, secretory phase of the menstrual cycle, and endometriosis. PLC indicates percentage of labeled cells.

Results

CXCR7 Is Overexpressed in Human Endometriosis

CXCR7 mRNA expression was analyzed in normal human eutopic endometrium in both the proliferative and secretory phase and compared to human endometriotic lesions. As shown in Figure 1A, CXCR7 mRNA levels were significantly higher (14-fold) in endometriotic lesions than in normal endometrium. Immunohistochemistry (IHC) analysis revealed that CXCR7 protein levels were undetectable or present at very low levels with a slight, although not significant, predominance in the secretory phase of the menstrual cycles (day 21 of normal ovulatory women) both in the epithelial and in stromal compartments (Figures 1B and 2) in normal endometrium tissue obtained from control patients without endometriosis. In contrast, expression of CXCR7 was clearly detected on >70% of ectopic glands with a predominance of the epithelial layer over the stromal compartment (Figures 1 and 2). CXCR7 is also expressed at low level in endothelial cells (mostly venule endothelium) in normal endometrium; however, a marked upregulation of CXCR7 occurred in endometriosis vasculature.

Specifically, in addition to endothelial cells, vascular smooth muscle cells into the endometriosis implants were markedly stained. Interestingly, fibromuscular cells associated with deep endometriosis were also markedly stained.³⁷

CXCR7 Is Overexpressed in Murine Model of Endometriosis

The analysis of endometriosis implants in mice was performed after 2 and 4 weeks after the engraftment of donor uterine fragments in peritoneal wall of immune and reproductive competent recipient mice. Results were compared with uteri of sham-treated mice. In endometriosis mice, CXCL12 mRNA levels were increased gradually from the day of endometriosis induction, reached a peak at 15th day, and regressed after 30 days. Consistently with human findings, CXCR7 expression was markedly higher in endometriosis in comparison with the normal uterus, without a significant difference between 2 and 4 weeks postengraftment (Figure 3A). IHC revealed higher staining compared to normal uteri, mostly in epithelial cells (Figure 3).

Figure 2. Representative images of *CXCR7* protein expression by IHC staining in eutopic endometrium and ectopic endometriosis. A, B, Normal endometrium proliferative phase (original magnification $\times 100$, $\times 400$, respectively). C, D, Normal endometrium secretory phase ($\times 100$, $\times 400$, respectively). E, Deep infiltrating endometriosis ($\times 200$). F, Deep infiltrating endometriosis, ectopic gland ($\times 400$). G, H, Endometrioma ($\times 100$, $\times 400$, respectively). *CXCR7* protein is highly expressed in deep endometriosis and endometrioma compared to phases in normal eutopic endometrium.

Discussion

In this study, we determined that *CXCR7* expression is increased in endometriosis in human as well as in a murine model when compared to the respective controls. Normal

endometrial epithelium and stroma showed undetectable or very low expression of *CXCR7*, without any significant changes across menstrual cycle phases, while endometriosis showed a dramatic *CXCR7* upregulation of both mRNA and

Figure 3. Expression of *CXCR7* and *CXCL12* in endometriosis of murine model. **A**, Expression of *CXCR7* and *CXCL12* in mouse ectopic lesion over 2 and 4 weeks was analyzed by qRT-PCR. *CXCL12* levels peaks at 15th day and regressed after 30 days, after induction of endometriosis while *CXCR7* levels stays at high levels even after 30 days. mRNA levels are expressed relative to transcript level in eutopic uterine donor tissue, set at 1.0. **B**, Representative images of IHC showing high levels of *CXCR7* protein expression in stroma and epithelial cells of ectopic uteri of endometriosis compared to sham control. **C**, Shows the percentage of labeled cells (PLC) based on IHC staining shown in **B**. Results are shown in mean $\pm$ SEM. * $P < .05$. IHC indicates Immunohistochemistry; qRT-PCR, quantitative real-time polymerase chain reaction.

protein. This finding confirmed previous immunostaining data showing that normal endometrium has very low or no *CXCR7* expression.³⁸ We further characterized the absence of significant effects exerted by ovarian steroids on *CXCR7* expression in normal endometrial tissue since no significant changes between the proliferative and secretory phase were detected. In normal endometrium, the *CXCR7* is also expressed in endothelial cells of some endometrial vessels. Smooth muscle

and pericytes are reduced in the superficial layer of the endometrium, and the most superficial vessels consist only of endothelial cells.³⁹ In the secretory phase, the growth of the subepithelial capillary plexus takes place and endothelial cells maintain a marked *CXCR7* staining. Endometriosis implants are typically characterized by glandular epithelium and stroma surrounded by abundant vascularization (as a result of neoangiogenesis) and myofibroblasts.²⁸ We showed that *CXCR7* is

upregulated and widely expressed in the vascular smooth muscle cells and in endothelial cell of endometriosis-associated vessels. This finding is in agreement with previous data showing that *CXCR7* exhibited robust staining in a large percentage of tumor vasculature from human malignancies.^{40,41}

CXCR7 has a crucial role in vascular remodeling in physiological as well as pathological conditions. *CXCR7* activation by *CXCL12* stimulates angiogenesis *in vivo* and promotes tube formation in human umbilical vein endothelial cells (HUVEC).⁴² *CXCR7* plays a key role in maintaining endothelial integrity, through which it regulates vascular response to endothelial denudation injury.^{42,43} Moreover, *CXCR7* activation induces directional migration and polarization of endothelial cells in response to *CXCL12*.⁴²

Interestingly, unlike normal endometrium, ectopic glands in endometriosis implants exhibit a positive staining with predominance in epithelial cells. This novel feature of ectopic glands confirms profound cellular dysregulation in endometriosis compared to normal endometrium.⁴⁴ Lastly, cells surrounding vessels thought to be myofibroblasts exhibit strong positive *CXCR7* staining in agreement with other pathological conditions characterized by fibroblast recruitment and fibrosis.⁴⁵

The mouse model of endometriosis recapitulated human features. Uterine grafting in the abdomen is associated with a tremendous increase in intralesion *CXCL12* expression after 2 and 4 weeks after grafting. This finding is associated with an increased expression of *CXCR7* demonstrating the existence of an upregulated *CXCL12-CXCR7* axis in endometriosis. This observation confirms the crucial role of chemokines in the endometriosis microenvironment. This hypothesis is also supported by adhesion studies demonstrating, *in vitro*, that *CXCR7* expression is regulated by inflammatory cytokines (Interleukin-1 β [IL-1 β], IL-8, and *CXCL12*) on endothelial cells and promotes maximal interactions when expressed concomitantly on both tumor cells and activated endothelium.^{29,40} *CXCR7* is also induced in human endothelial cells and in bone marrow-derived mesenchymal stem cells under hypoxic and acidic conditions, consistent with the endometriosis microenvironment.⁴⁶

Based on the current knowledge of the *CXCL12-CXCR4/CXCR7* axis, we hypothesize that it has a dual role in the endometriosis microenvironment: (a) enhancing local proliferative and anti-apoptotic cellular pathways in different cellular populations harboring the receptors and (b) promoting bone marrow-derived stem cell trafficking into endometriosis favoring the development of ectopic lesions. Future studies will address the functional implications of these findings. In conclusion, specific upregulation of *CXCR7* in different cellular populations of endometriosis microenvironment may represent a novel target for new nonhormonal treatments of this chronic inflammatory disease.

Declaration of Conflicting Interests

The author(s) declared no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIH U54 HD052668 and R01 HD076422.

ORCID iD

R Mamillapalli, PhD <http://orcid.org/0000-0002-4022-8910>

References

1. Bulun SE. Endometriosis. *N Engl J Med*. 2009;360(3):268-279.
2. Giudice LC. Clinical practice. Endometriosis. *N Engl J Med*. 2010;362(25):2389-2398.
3. Taylor HS, Giudice LC, Lessey BA, et al. Treatment of endometriosis-associated pain with elagolix, an Oral GnRH antagonist. *N Engl J Med*. 2017;377(1):28-40.
4. Naqvi H, Mamillapalli R, Krikun G, Taylor HS. Endometriosis located proximal to or remote from the uterus differentially affects uterine gene expression. *Reprod Sci*. 2016;23(2):186-191.
5. Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. *Obstet Gynecol Clin North Am*. 2012;39(4):535-549.
6. Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. *Stem Cells*. 2007;25(8):2082-2086.
7. Pluchino N, Taylor HS. Endometriosis and stem cell trafficking. *Reprod Sci*. 2016;23(12):1616-1619.
8. Kao AP, Wang KH, Chang CC, et al. Comparative study of human eutopic and ectopic endometrial mesenchymal stem cells and the development of an *in vivo* endometriotic invasion model. *Fertil Steril*. 2011;95(4):1308-1315.e1301.
9. Lagana AS, Sturlese E, Retto G, Sofo V, Triolo O. Interplay between misplaced Mullerian-derived stem cells and peritoneal immune dysregulation in the pathogenesis of endometriosis. *Obstet Gynecol Int*. 2013;2013:527041.
10. Patel BG, Rudnicki M, Yu J, Shu Y, Taylor RN. Progesterone resistance in endometriosis: origins, consequences and interventions. *Acta Obstet Gynecol Scand*. 2017;96(6):623-632.
11. Cakmak H, Taylor HS. Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. *Semin Reprod Med*. 2010;28(1):69-74.
12. Evans-Hoeker E, Lessey BA, Jeong JW, et al. Endometrial BCL6 overexpression in eutopic endometrium of women with endometriosis. *Reprod Sci*. 2016;23(9):1234-1241.
13. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. *Pharmacol Rev*. 2000;52(1):145-176.
14. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. *Immunity*. 2000;12(2):121-127.
15. Zlotnik A, Yoshie O. The chemokine superfamily revisited. *Immunity*. 2012;36(5):705-716.
16. Balkwill FR. The chemokine system and cancer. *J Pathol*. 2012;226(2):148-157.
17. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. *Cancer Cell*. 2011;19(2):257-272.

18. Tsutsumi A, Okada H, Nakamoto T, Okamoto R, Yasuda K, Kanzaki H. Estrogen induces stromal cell-derived factor 1 (SDF-1/CXCL12) production in human endometrial stromal cells: a possible role of endometrial epithelial cell growth. *Fertil Steril*. 2011;95(1):444-447.
19. Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. *Hum Reprod Update*. 2013;19(4):406-418.
20. Laschke MW, Giebels C, Menger MD. Vasculogenesis: a new piece of the endometriosis puzzle. *Hum Reprod Update*. 2011;17(5):628-636.
21. Ruiz A, Salvo VA, Ruiz LA, Baez P, Garcia M, Flores I. Basal and steroid hormone-regulated expression of CXCR4 in human endometrium and endometriosis. *Reprod Sci*. 2010;17(10):894-903.
22. Leconte M, Chouzenoux S, Nicco C, et al. Role of the CXCL12-CXCR4 axis in the development of deep rectal endometriosis. *J Reprod Immunol*. 2014;103:45-52.
23. Virani S, Edwards AK, Thomas R, Childs T, Tayade C. Blocking of stromal cell-derived factor-1 reduces neoangiogenesis in human endometriosis lesions in a mouse model. *Am J Reprod Immunol*. 2013;70(5):386-397.
24. Wang X, Mamillapalli R, Mutlu L, Du H, Taylor HS. Chemoattraction of bone marrow-derived stem cells towards human endometrial stromal cells is mediated by estradiol regulated CXCL12 and CXCR4 expression. *Stem Cell Res*. 2015;15(1):14-22.
25. Moridi I, Mamillapalli R, Cosar E, Ersoy GS, Taylor HS. Bone marrow stem cell chemotactic activity is induced by elevated CXCL12 in endometriosis. *Reprod Sci*. 2016.
26. Sierro F, Biben C, Martinez-Munoz L, et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. *Proc Natl Acad Sci U S A*. 2007;104(37):14759-14764.
27. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *J Biol Chem*. 2005;280(42):35760-35766.
28. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C. CXCR7 impact on CXCL12 biology and disease. *Trends Mol Med*. 2013;19(1):12-22.
29. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med*. 2006;203(9):2201-2213.
30. Levoye A, Balabanian K, Baleux F, Bachelier F, Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. *Blood*. 2009;113(24):6085-6093.
31. Vela M, Aris M, Llorente M, Garcia-Sanz JA, Kremer L. Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. *Front Immunol*. 2015;6:12.
32. Wu YC, Tang SJ, Sun GH, Sun KH. CXCR7 mediates TGFbeta1-promoted EMT and tumor-initiating features in lung cancer. *Oncogene*. 2016;35(16):2123-2132.
33. Liu Y, Carson-Walter E, Walter KA. Targeting chemokine receptor CXCR7 inhibits glioma cell proliferation and mobility. *Anticancer Res*. 2015;35(1):53-64.
34. Sakr S, Naqvi H, Komm B, Taylor HS. Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment. *Endocrinology*. 2014;155(4):1489-1497.
35. Barr A, Manning DG. *Proteins Techniques of Analysis*. Boca Raton, FL: CRC; 1999:227-245.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods*. 2001;25(4):402-408.
37. van Kaam KJ, Schouten JP, Nap AW, Dunselman GA, Groothuis PG. Fibromuscular differentiation in deeply infiltrating endometriosis is a reaction of resident fibroblasts to the presence of ectopic endometrium. *Hum Reprod*. 2008;23(12):2692-2700.
38. Walentowicz-Sadlecka M, Sadlecki P, Bodnar M, et al. Stromal derived factor-1 (SDF-1) and its receptors CXCR4 and CXCR7 in endometrial cancer patients. *PLoS One*. 2014;9(1):e84629.
39. Kohonen G, Campbell S, Jeffers MD, Cameron IT. Spatially regulated differentiation of endometrial vascular smooth muscle cells. *Hum Reprod*. 2000;15(2):284-292.
40. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. *Proc Natl Acad Sci USA*. 2007;104(40):15735-15740.
41. Maishi N, Ohga N, Hida Y, et al. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. *Pathol Int*. 2012;62(5):309-317.
42. Zhang M, Qiu L, Zhang Y, Xu D, Zheng JC, Jiang L. CXCL12 enhances angiogenesis through CXCR7 activation in human umbilical vein endothelial cells. *Sci Rep*. 2017;7(1):8289.
43. Hao H, Hu S, Chen H, et al. Loss of endothelial CXCR7 impairs vascular homeostasis and cardiac remodeling after myocardial infarction: implications for cardiovascular drug discovery. *Circulation*. 2017;135(13):1253-1264.
44. Logan PC, Yango P, Tran ND. Endometrial stromal and epithelial cells exhibit unique aberrant molecular defects in patients with endometriosis. *Reprod Sci*. 2018;25(1):140-159.
45. Cao Z, Lis R, Ginsberg M, et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. *Nat Med*. 2016;22(2):154-162.
46. Liu H, Xue W, Ge G, et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1alpha in MSCs. *Biochem Biophys Res Commun*. 2010;401(4):509-515.